Laxxon Medical and Adare Pharma Solutions Announce Joint Cooperation for Production of cGMP 3D Printed Oral Dosage Forms in Europe and US
Newsroom
The cooperation between Laxxon and Adare enables the clinical and commercial production of advanced drug delivery systems at Adare’s cGMP facilities in Italy and US.
Scientific Publications
Laxxon 3D Screen Printing Technology Enables Fabrication of Oral Drug Dosage Forms with Freely Tailorable Release Profiles
A study published in the International Journal of Pharmaceutics explores the advancement of pharmaceutical oral dosage forms and the feasibility of manufacturing composite tablets with freely tailorable drug release profiles using 3D screen printing (3DSP) technology.
Scientific Publications
Pharmaceutics 3D Screen Printing Offers Unprecedented Anticounterfeiting Strategies for Oral Solid Dosage Forms Feasible for Large Scale Production
3D screen printing (3DSP), an additive manufacturing technology that enables large-scale production, offers unique opportunities to combat counterfeit drugs.
Newsroom
Laxxon Medical Announces Development Program for Non-Invasive, 3D Printed Oral GLP-1 Asset, Offering an Alternative to GLP-1 Injections on Market
LXM.2 is an enterically coated oral solid tablet consisting of a GLP-1 receptor agonist combined with a permeation enhancer intended to increase bioavailability.
Laxxon is dedicated to revolutionizing the pharmaceutical industry with better, smarter drug delivery solutions for patients.
With our proprietary SPID®-Technology, our additive manufacturing platform is pioneering a new generation of oral medications.
For new and established pharmaceutical drugs, SPID®-Technology unlocks innovative drug delivery advancements paired with fast-tracked market access and extensive IP protection to yield disruptive opportunities in the pharmaceutical space.
Business Model
We provide drug formulation and delivery solutions that enable patent life extension for generics, significantly improved bioavailability, customized release profiles for novel drugs and cost-effective production from small batches to large volumes.
Our business model allows us to develop our own in-house patented generic drug development pipeline with scientific expertise spanning several therapeutic areas.
Our Commercial Solutions for Pharma
In the next 10 years, 150+ drugs will come off patent protection. These drugs are worth over $100B in sales.
Laxxon has both an external pipeline and in-house Advanced Patented Generic pipeline.
03.
Pipeline consists of 13 in-house products and 3 products that are being developed for external clients
All products created with our SPID®-Technology manufacturing approach are patent protected,
whether engineered in-house or with an external partner
Our Mission
Laxxon Medical is dedicated to engineering patented 3D pharmaceutical solutions which optimize products and benefit patients.
The basis of Laxxon's pharmaceutical solutions is our cutting-edge 3D screen printing technology and the extensive intellectual property surrounding it.
Our commitment to innovation and health is fueled by the expertise, integrity, agility, and diversity of the Laxxon team.
Laxxon strives to accelerate pharmaceutical progress globally by establishing ourselves as the leader in the field of 3D printed drugs.
Events
